GSK-Medicago Announce Positive Results For Trial Covid Vaccine
Mohammad Ali (@ChaudhryMAli88) Published December 07, 2021 | 10:50 PM
London, Dec 7 (UrduPoint / Pakistan Point News - 7th Dec, 2021 ) :British pharma giant GlaxoSmithKline and Canada's Medicago said on Tuesday they had seen positive results with a candidate Covid-19 vaccine in a large-scale trial, although the tests were carried out before the Omicron variant emerged.
In the Phase 3 trial, "the overall vaccine efficacy rate against all variants of SARS-COV-2 was 71 percent", the two companies said in a statement, using the technical term for the novel coronavirus.
What's more, it was 75.3 percent effective against the "globally dominant Delta variant".
But they added that the Omicron variant was not circulating at the time of the study on 24,000 adults in six countries -- Canada, the United States, Britain, Mexico, Argentina, and Brazil.
The figures are not comparable with studies on existing vaccines, most of which were carried out while the original virus strain was circulating.
"During the study, no related serious adverse events were reported and reactogenicity (side effects) was generally mild to moderate and transient; symptoms lasting on average only one to three days," the companies said.
Only a small number of severe virus cases were detected among the trial patients, all of them in the group that received the placebo rather than the vaccine.
Medicago says its vaccine, which uses particles that mimic the properties of viruses to stimulate the immune system, is based on plants.
"Because the virus-like particles lack core genetic material, they are non-infectious and unable to replicate," the company said.
"Based on these results, Medicago will imminently seek regulatory approval from Health Canada as part of its rolling submission," GSK and Medicago said, although "the vaccine candidate is not yet approved by any regulatory authority".
They have also filed for approval from US and British authorities.
As well as working with France's Sanofi, Germany's CureVac and South Korea's SK Bioscience on potential vaccines, GSK is developing potential treatments for Covid-19.
One, a monoclonal antibody treatment created alongside California's Vir Biotechnology, was approved by British regulators last week.
Related Topics
Recent Stories
Selection committee dissolved over Pakistan women cricket team's poor performanc ..
Punjab CM Maryam Nawaz in police uniform at Chung police center
Currency Rate In Pakistan - Dollar, Euro, Pound, Riyal Rates On 25 April 2024
Today Gold Rate in Pakistan 25 April 2024
Mired in crisis, Boeing reports another loss
Session Awarding Ceremony 2024 held at Cadet College Muzaffarabad
Austrian ski great Hirscher to make comeback under Dutch flag
Pakistan, Japan agrees to convene 'Economic Policy Dialogue'
FM Dar conveys deepest sympathy on torrential rains devastation in UAE
Spain PM Sanchez says weighing resignation after wife's graft probe
Tennis: ATP/WTA Madrid Open results - 1st update
Long-lost Klimt portrait auctioned off for 30 mn euros
More Stories From Miscellaneous
-
PDMA predicts gusty wind, rain with thunder, hails
2 days ago -
Iranian president Raisi given guard of honour at PM House
3 days ago -
Intellectuals, writers accolades Naseer Mirza on his literary contribution
4 days ago -
Bahawalpur Adabi Sangat hosts memorable mushaira
4 days ago -
Cattle farming vital to alleviate poverty in rural areas
4 days ago -
Pakistan: A land of tourism, archeological wonders
4 days ago
-
Transforming education sector: from job hunters to job creators
6 days ago -
Amjad Bobby remembered on 19th death anniversary for timeless contributions to music
10 days ago -
Legendary actor Nadeem’s 26 films released on Eid-ul-Fitr days in 50 years
11 days ago -
Besant Hall Cultural Centre to celebrate evening with Sanam Marvi on 26 April
11 days ago -
Radio Bahawalpur presents program “Eidi Shidi”
14 days ago -
Radio Bahawalpur to broadcast Eid programs
16 days ago